Immix Biopharma Inc. (NASDAQ: IMMX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT IMMIX BIOPHARMA INC.

Immix Biopharma Inc. (NASDAQ: IMMX)
Listen to this Section


$7.88
-0.5370 ( -6.38% ) 615.4K

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Market Data


Open $7.88
Previous Close $8.42
Volume 615.4K
Market Cap $600.84M
Day Range $7.81 - $9.27
52 Week Range $1.94 - $11.61
Shares Outstanding 71.19M
Change % -6.38%
Net Change ▼ -0.5370
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryMedicinal Chemicals and Botanical Products
IPO Year2021
CountryUnited States
UnderwriterThinkEquity, more

Insider Ownership Transactions

Total Amount Purchased: -1,762,697.00

Date Type Amount Purchased Purchaser
2025-09-17 Buy 2500.00 Rachman Ilya M
2025-09-17 Buy 2600.00 Morris Gabriel S
2025-06-20 Buy 2225.00 Morris Gabriel S
2025-06-20 Buy 2178.00 Rachman Ilya M
2025-06-20 Buy 2225.00 Morris Gabriel S
2024-12-26 Buy 7700.00 Hsu Jason
2024-08-26 Buy 15000.00 Hsu Jason
2024-08-19 Buy 10000.00 Ng Carey
2024-07-31 Buy 3200.00 Hsu Jason
2024-06-21 Sale -340000.00 Morris Gabriel S

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jun 23, 2025
4 Insider transactions 1 Jun 23, 2025
4 Insider transactions 1 Jun 23, 2025
4 Insider transactions 1 Jun 23, 2025
4 Insider transactions 1 Jun 23, 2025
4 Insider transactions 1 Jun 20, 2025
4 Insider transactions 1 Jun 20, 2025
8-k 8K-related 15 Jun 03, 2025

Latest News


× Before browsing our site, please accept our cookies policy